| 杨水清,蒋玉华,郭一雲,张玉江,廖 勇.补肺活血胶囊联合喘可治注射液对慢性阻塞性肺疾病稳定期患者肺功能、 血气指标以及血液流变学的影响[J].现代生物医学进展英文版,2021,(10):1926-1929. |
| 补肺活血胶囊联合喘可治注射液对慢性阻塞性肺疾病稳定期患者肺功能、 血气指标以及血液流变学的影响 |
| The Effect of Bufeihuoxue Capsule Combined with Chuankezhi Injection on Pulmonary Function, Blood Gas Index and Hemorheology in Patients with Stable Chronic Obstructive Pulmonary Disease |
| Received:September 04, 2020 Revised:September 27, 2020 |
| DOI：10.13241/j.cnki.pmb.2021.10.026 |
| 中文关键词: 补肺活血胶囊 喘可治注射液 慢性阻塞性肺疾病 稳定期 肺功能 血气指标 血液流变学 |
| 英文关键词: Bufeihuoxue capsule Chuankezhi injection Chronic obstructive pulmonary disease Stable period Pulmonary function Blood gas index Hemorheology |
| 基金项目:湖南省中医药管理局科研项目(201249) |
|
| Hits: 795 |
| Download times: 509 |
| 中文摘要: |
| 摘要 目的：探讨补肺活血胶囊联合喘可治注射液对慢性阻塞性肺疾病（COPD）稳定期患者肺功能、血气指标以及血液流变学的影响。方法：选取我院于2017年8月到2019年12月期间接收的126例COPD稳定期患者，按照随机数字表法将患者分为对照组（n=63）和研究组（n=63），对照组给予静注喘可治注射液，研究组在对照组的基础上联合补肺活血胶囊治疗，均治疗12周。比较两组患者疗效、肺功能、血气指标以及血液流变学，记录两组治疗期间不良反应情况。结果：治疗12周后，研究组的临床总有效率84.13%（53/63）高于对照组66.67%（42/63）（P<0.05）。两组第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、FEV1/FVC均较治疗前升高，且研究组高于对照组（P<0.05）。两组治疗12周后动脉氧分压（PaO2）较治疗前升高，且研究组高于对照组（P<0.05）；两组治疗12周后动脉二氧化碳分压（PaCO2）较治疗前降低，且研究组低于对照组（P<0.05）。两组血浆黏度、纤维蛋白原、全血黏度水平均下降，研究组较对照组低（P<0.05）。两组不良反应发生率比较无差异(P>0.05)。结论：COPD稳定期患者在喘可治注射液的基础上联合补肺活血胶囊治疗，血气指标、肺功能以及血液流变学可得到显著改善，且用药安全性好，疗效较好。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect of bufeihuoxue capsule combined with Chuankezhi Injection on pulmonary function, blood gas index and hemorheology in patients with stable chronic obstructive pulmonary disease（COPD）. Methods: 126 patients with stable COPD received by our hospital from August 2017 to December 2019 were selected, the patients were divided into control group (n=63) and study group (n=63) according to the random number table method. The control group was given Chuankezhi injection, the study group was treated with bufeihuoxue Capsule on the basis of the control group, all patients were treated for 12 weeks. The therapeutic effect, pulmonary function, blood gas index and hemorheology of the two groups were compared, and the adverse reactions during the treatment were recorded. Results: 12 weeks after treatment, the total clinical effective rate of the study group was 84.13% (53/63) higher than 66.67% (42/63) of the control group (P<0.05). The forced expiratory volume in the first second (FEV1), forced vital capacity (FVC) and FEV1/FVC in the two groups were higher than those before treatment, and the study group were higher than those of the control group(P<0.05). The partial pressure of oxygen（PaO2）of the two groups increased at 12 weeks after treatment, and the study group was higher than that of the control group (P<0.05). The arterial partial pressure of carbon dioxide（PaCO2）of the two groups decreased after 12 weeks treatment, and the study group was lower than that of the control group(P<0.05). The levels of whole blood viscosity, plasma viscosity and fibrinogen in the two groups decreased , and the study group were lower than those of control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion: Bufeihuoxue capsule combined with Chuankezhi injection can improve the blood gas, pulmonary function, index and hemorheology in the patients with stable COPD, its curative effect is better, and it's in good drug safety. |
|
View Full Text
View/Add Comment Download reader |
| Close |
